Latest oppositions filed by Novartis Ag

This table presents recent patent oppositions filed by Novartis Ag against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP2784084Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofGENENTECH, INC.Jul 24, 2019
EP2888626Contact Lens With A Hydrophilic LayerOCULAR DYNAMICS, LLCJan 18, 2019
EP2794727Ionic Silicone HydrogelsJOHNSON & JOHNSON VISION CARE INC.Oct 24, 2018
EP2705073Macroinitiator Containing Hydrophobic SegmentJOHNSON & JOHNSON VISION CARE INC.Oct 10, 2018
EP2855545Polymers And Nanogel Materials And Methods For Making And Using The SameJOHNSON & JOHNSON VISION CARE INC.Aug 1, 2018
EP1623269Hydrogel Contact Lenses And Package Systems And Production Methods For SameCOOPERVISION INTERNATIONAL HOLDING COMPANY, LPFeb 9, 2018

The following table provides an overview of the latest patents of Novartis Ag that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3124018Apr 24, 2024Oral Formulations Of Deferasirox2
EP4159204Feb 14, 2024Novel Pharmaceutical Composition4
EP4159205Feb 14, 2024Novel Pharmaceutical Composition5
EP3272764Feb 7, 2024Method For Affinity Chromatography1
EP4108259Jan 3, 2024Process For Concentration Of Antibodies And Therapeutic Products Thereof1
EP3023095Nov 8, 2023Direct Compression Formulation And Process3
EP2501384Nov 1, 2023Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity5
EP3897647Nov 1, 2023Combinations Of A Hdm2-P53 Interaction Inhibitor And A Bcl2 Inhibitor And Their Use For Treating Cancer1
EP3536776Oct 25, 2023Novel Vertebrate Cells And Methods For Recombinantly Expressing A Polypeptide Of Interest1
EP3626270Oct 11, 2023New Use16